Last reviewed · How we verify
Placebo Tablet or Capsule
Placebo Tablet or Capsule is a Small molecule drug developed by Debiopharm International SA. It is currently FDA-approved for Clinical trial control arm (non-therapeutic use). Also known as: Placebo.
A placebo tablet or capsule contains no active pharmaceutical ingredient and produces therapeutic effects solely through the placebo effect.
Placebo tablets or capsules are used as a control intervention in clinical trials to compare the effects of other treatments. Placebo has been studied in various conditions, including obesity, diabetes, and chronic obstructive pulmonary disease, as part of trials examining the thermogenic properties of other substances.
At a glance
| Generic name | Placebo Tablet or Capsule |
|---|---|
| Also known as | Placebo |
| Sponsor | Debiopharm International SA |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Placebo formulations are inert preparations used as control comparators in clinical trials to distinguish the true pharmacological effects of an active drug from psychological and contextual healing responses. They rely on patient expectation, the therapeutic ritual, and natural disease progression or regression to produce measurable clinical outcomes. Placebos are essential tools in evidence-based medicine for establishing drug efficacy.
Approved indications
- Clinical trial control arm (non-therapeutic use)
Common side effects
- Placebo effect (perceived symptom improvement)
- Nocebo effect (perceived adverse events)
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn) (PHASE3)
- A Study of LY4268989 (MORF-057) in Healthy Participants (PHASE1)
- Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC) (PHASE3)
- A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis. (PHASE3)
- Low-dose Naltrexone for Post-COVID Fatigue Syndrome (PHASE2)
- Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991) (PHASE3)
- Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function (PHASE3)
- A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo Tablet or Capsule CI brief — competitive landscape report
- Placebo Tablet or Capsule updates RSS · CI watch RSS
- Debiopharm International SA portfolio CI
Frequently asked questions about Placebo Tablet or Capsule
What is Placebo Tablet or Capsule?
How does Placebo Tablet or Capsule work?
What is Placebo Tablet or Capsule used for?
Who makes Placebo Tablet or Capsule?
Is Placebo Tablet or Capsule also known as anything else?
What development phase is Placebo Tablet or Capsule in?
What are the side effects of Placebo Tablet or Capsule?
Related
- Manufacturer: Debiopharm International SA — full pipeline
- Indication: Drugs for Clinical trial control arm (non-therapeutic use)
- Also known as: Placebo
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing